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ABSTRACT
RNA interference (RNAi) can be induced in vitro
either by application of synthetic short interfering
RNAs (siRNAs), or by intracellular expression of
siRNAs or short hairpin RNAs (shRNAs) from trans-
fected vectors. The most widely used promoters for
siRNA/shRNA expression are based on polymerase
III (Pol III)-dependent transcription. We developed an
alternative vector for siRNA/shRNA expression,
using a mouse RNA polymerase I (Pol I) promoter.
Pol I-dependent transcription serves in cells for pro-
duction of ribosomal RNA (rRNA), and as such, is
ubiquitously and stably active in different cell types.
As Pol I-dependent transcription is highly species-
specific, Pol I-based system provides an important
biosafety advantage with respect to silencing of
genes with unknown functions.
INTRODUCTION
RNA interference (RNAi) is a post-transcriptional gene-
silencing mechanism, by which a speciﬁc degradation of
mRNA is induced by homologous double-stranded RNAs
(dsRNAs). Since its discovery, RNAi has rapidly evolved
into a powerful technique to knock-down gene expression
and gained ground as an indispensable tool to study gene
function both in vitro and in vivo [reviewed in (1–3)]. In
plants and animals, such as Caenorhabditis elegans and
Drosophila, RNAi can be activated by long dsRNAs, which
are processed by an intracellular machinery to short interfer-
ing RNAs (siRNAs) [(4–7); reviewed in (8)].
However, in mammalian cells long dsRNAs cause general
translational inhibition and unspeciﬁc RNA degradation
(9,10). These effects can be avoided by introducing in vitro-
synthesized siRNAs into the cells (9,10). The resulting silenc-
ing is very pronounced, in particular due to the high siRNAs
transfection efﬁciency, greatly exceeding the one for DNA
vectors. Therefore, this technique has been widely adopted
in experimental paradigms, such as pathway proﬁling and
drug screening [reviewed in (11,12)]. Its major drawback,
however, resides in the transient nature of silencing. Studies
of gene function often require the establishment of cell lines
or transgenic organisms, in which siRNAs should be expres-
sed from stably integrated cassettes. In expression vectors,
siRNAs are normally processed from a short hairpin RNA
(shRNA)  70 nt in length, structurally similar to naturally
occurring microRNA (miRNA) precursor. This sequence
should fulﬁl strict length requirements to result in an effective
siRNA. Transcripts generated from conventional RNA poly-
merase II (Pol II) promoter-based vectors are therefore not
suitable for such a purpose, as they undergo extensive post-
transcriptional modiﬁcations, such as capping and poly(A)
tailing (10). To circumvent this problem, RNA polymerase
III (Pol III) promoter-driven cassettes were developed
(13–16). Recently, the use of a cytomegalovirus (CMV)
promoter to generate siRNAs was made possible by insertion
of a human miRNA miR-30 precursor and neighboring
genomic sequences into the expression vector (17). Here,
we present an alternative method for expression of siRNAs,
using ribosomal transcription units driven by RNA poly-
merase I (Pol I) promoters. Similarly to Pol III-driven tran-
scription, Pol I-mediated transcription is very robust,
ubiquitous, devoid of extensive RNA modiﬁcations and is
characterized by clearly deﬁned transcription start and ter-
mination sites (18). In addition, it has no limits for transcript
size, and even more importantly, possesses a high species
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doi:10.1093/nar/gkl1045speciﬁcity (19). This latter feature, which is unique among all
RNA polymerases, provides an interesting potential regarding
biosafety of experiments.
MATERIALS AND METHODS
Cloning
All Pol I-containing plasmids described here were derived
from the ribosomal minigenes pW (20), kindly provided by
Dr J. Cavaille, Universite ´ Paul Sabatier, Toulouse, France,
and pE3SP (21). Part of the pW vector was ampliﬁed in
two steps using primers P1–P4 (Figure 1). All primers were
synthesized by MWG Biotech. Primer sequences were as
follows: P1 (M13r-based): 50-CAATTTCACACAGGAAAC-
AGCTATGACC-30; P2: 50-ATGTCTTCGAAGTCCATGGT-
ACCTATCTCCAGGTC-30;P 3 :5 0-ACCATGGACTTCGA-
AGACTATCCCCCCCAACTTCG-30; P4 (M13f-based): 50-
GTCACGACGTTGTAAAACGACGGCCAGT-30. As a ﬁrst
step, the distal arms of the construct were PCR ampliﬁed
using P1 and P2, or P3 and P4, respectively. PCR of a total
volume of 50 ml were carried out, with each PCR containing
200 mM each dNTP (Roche), 1 mM of each primer, 100 ng of
plasmid pW and 2 U of Taq polymerase (Roche). Thermocy-
cling began with 5 min at 95 C followed by 2 cycles of 45 s
at 95 C, 60 s at 50 C and 45 s at 72 C, followed by 18 cycles
of 45 s at 95 C, 60 s at 60 C and 45 s at 72 C. PCR products
were puriﬁed with the QiaQuick Gel Extraction Kit (Qiagen)
according to the manufacturer’s protocol and dissolved in
40 ml of elution buffer. Both arms of the construct were
joined in a PCR using primers P1 and P4. First, the annealing
reaction of a total volume of 100 ml was carried out, using
200 mM of each dNTP, 1 ml of each product from the ﬁrst
step PCR (P1–P2 and P3–P4, respectively) and 3 U of Taq
polymerase. The annealing reaction required ﬁve cycles of
thermocycling, each of 60 s at 95 C, 2 min at 50 C and
60 s at 72 C. Subsequently, primers (P1 and P4, 1 mM
each) were added, and the PCR was carried out for 20 cycles
of 45 s at 95 C, 60 s at 60 C and 45 s at 72 C. PCR products
were digested with PstI and EcoRI (restriction sites were
incorporated into the P1 and P4 primers, respectively), and
subcloned either into the vector pW or pE3SP, also digested
with PstI and EcoRI, resulting in pW-bc and pE3SP-bc (‘bc’
standing for ‘basic construct’). To generate the pW-MCS
(multiple cloning site) and pE3SP-MCS plasmids, oligonu-
cleotides MCS.s and MCS.as were annealed and subcloned
into BbsI/KpnI digested pW-bc and pE3SP-bc, respectively.
Oligonucleotide sequences were as follows: MCS.s: 50-GTC-
TTCGAAGATGTCGAGCTCTAGATATCAATTGGTAC-
CATGGGAAGACTA-30;M C S . a s :5 0-GGGATAGTCTTC-
CCATGGTACCAATTGATATCTAGAGCTCGAGATCT-
TCGAAGACGTAC-30.
To generate the new RNAi mediating plasmids pW-shLuc
and pE3SP-shLuc for knock-down of the ﬁreﬂy luciferase
reporter, shLuc-s and shLuc-as oligonucleotides were
annealed and subcloned into the BbsI-digested pW-MCS
and pE3SP-MCS, respectively (Figure 2). This restriction
site lies within the formerly introduced MCS of pW-MCS.
Oligonucleotide sequences were as follows: shLuc.s: 50-AGG-
TGGATTCCAATTCAGCGGGAGCCACCTGATGAAGC-
TTGATCGGGTGGCTCTCGCTGAGTTGGAATCCAT-30;
shLuc.as: 50-GGGAATGGATTCCAACTCAGCGAGAGC-
CACCCGATCAAGCTTCATCAGGTGGCTCCCGCTGA-
ATTGGAATCC-30.
Generation of pE3SP-shErk2, which was aimed at silencing
Erk2, the endogenous MAP kinase p42, followed the same
strategy as for cloning of pE3SP-shLuc. The oligonucleotides
shErk2-s and shErk2-as were annealed and also subcloned
into the BbsI-digested pE3SP-MCS. Oligonucleotide seq-
uences were as follows: shErk2-s: 50-AGGTGGAAGATCT-
GAATTGTATAATAAGAAGCTTGTTATTATACAATTC-
AGATCTTCCAT-30; shErk2-as: 50-GGGAATGGAAGA-
TCTGAATTGTATAATAACAAGCTTCTTATTATACAA-
TTCAGATCTTCC-30. To have a proper control for the
speciﬁcity of our RNAi effect on Erk2, we produced a control
vector expressing a shRNA that targets an Erk2-unrelated
Figure 1. Construction of the vectors pW-bc and pE3SP-bc. Part of the pW
ribosomal minigene was PCR amplified in two steps. First, two fragments
were generated using primers P1 and P2, or P3 and P4, respectively. Second,
both fragments were joined by PCR with primers P1 and P4. The restriction
sites PstI and EcoRI, introduced through PCR primers P1 and P4, were used
to insert the resulting fragment into the pW and pE3SP (pE) vector
backbones. P, mouse Pol I promoter; Tx, transcription termination signal; bc,
basic construct; E, enhancer.
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same cloning strategy as before. Oligonucleotides shCon-
s and shCon-as were annealed and subcloned into BbsI-
digested pE3SP-MCS. Oligonucleotides were as follows:
con-s: 50-AGGTGTACATGTGTAATAGCTCCTTCAAGA-
GAGGAGCTATTACACATGTACAT-30; con-as: 50-GGGA-
ATGTACATGTGTAATAGCTCCTCTCTTGAAGGAGCT-
ATTACACATGTAC-30.
Cell culture
FM3A cells were cultured in RPMI 1640 medium with 10%
Newborn Serum. HEK293, HT22, HN9, Neuro-2a and HeLa
cells were cultured in DMEM (Invitrogen) supplemented with
10% heat-inactivated fetal calf serum (FCS) (Invitrogen), 2
mM glutamine (Invitrogen) and 1% antibiotic-antimycotic
mixture (penicillin–streptomycin–amphotericin) (Invitrogen)
at 37 C in a humidiﬁed 5% CO2 incubator.
IDG3.2 embryonic stem (ES) cells were grown on gelatine-
coated tissue culture plates in ES cell medium (DMEM,
15% FCS, 2 mM L-glutamine, 20 mM HEPES, 1 mM
sodium pyruvate, non-essential amino acids, 0.1 mM
b-mercaptoethanol and 1500 U/ml leukaemia inhibiting fac-
tor (Chemicon).
In vitro transcription assays
Nuclear extracts were prepared from exponentially growing
FM3A cells. To assay Pol I-speciﬁc transcription, 25 ml assays
contained 50 ng of template DNA (pE3SP-shLuc), 30 mgo f
nuclear extract proteins, 12 mM Tris–HCl (pH 7.9), 0.1 mM
EDTA, 5 mM MgCl2, 80 mM KCl, 10 mM creatine phosphate,
12% (v/v) glycerol, 0.66 mM each of ATP, GTP and CTP,
0.012 mM UTP and 0.1 mCi [a-
32P]UTP (5000 Ci/mmol,
Perkin–Elmer). For Pol III-speciﬁc transcription, assays con-
tained 500 ng of template DNA (pU6-shLuc), 30 mg of nuclear
extract proteins, 12 mM HEPES-KOH (pH 7.9), 0.14 mM
EDTA, 5 mM MgCl2, 60 mM KCl, 1 mM creatine phosphate,
3 mM DTT, 12% (v/v) glycerol, 0.4 mM each of ATP, GTP
and CTP, 0.004 mM UTP and 0.1 mCi [a-
32P]UTP (5000
Ci/mmol, Perkin–Elmer). Transcription reactions were carried
out in the absence or presence of a-amanitin (200 mg/ml,
Roche). After incubation for 60 min at 30 C, RNA was
extracted and analyzed on non-denaturing 6% polyacrylamide
gels.
Transfections
For the reporter assays, we transfected different human (HEK
293, HeLa) and mouse cell lines (HT22, HN9, Neuro-2a).
Cells were plated onto 24-well plates at a density of 2 ·
10
5 cells/well (HEK293 cells) or 8 · 10
4 cells/well (HT22
cells). HN9, Neuro-2a and HeLa cells were plated at different
cell numbers. They where grown until they reached a conﬂu-
ency of 90–95% and then transfected. Each well contained
500 ml of the respective culture medium but without
antibiotics/antimycotics. Cells were transfected either with
Effectene (Qiagen) or Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol.
For analysis in western blots, HN9 cells were cultured and
transfected in the same way as above but in 6-well format
using 2 ml of medium per well. To achieve a high transfection
efﬁciency, we additionally transfected mouse ES cells
(IDG3.2 ES cells) via electroporation. Thereby, 2 · 10
6 cells
were used in a volume of 800 ml phosphate-buffered saline
(PBS) by applying an electrical ﬁeld of 330 V to 4 mm
cuvettes (Bio-Rad). Afterwards cells were replated into one
10 cm culture dish and the medium was replaced 24 h later.
Plasmids pGL3-Con and pRL-SV40 expressing ﬁreﬂy and
Renilla luciferases, were purchased from Promega. pU6
empty vector and pU6-shLuc expressing shRNA targeting
ﬁreﬂy luciferase (pSHAG and pSHAG-FF, respectively
in original nomenclature) were kindly provided by Prof.
G. Hannon (Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY). The total amount of plasmid DNA per well
was kept equal and adjusted either with pBluescript (Strata-
gene) or pcDNA3 (Invitrogen) if needed. All transfections
were done at least in duplicate.
Dual luciferase assay
Fireﬂy and Renilla luciferase activities were measured
using the Dual luciferase assay kit (Promega) according to
the manufacturer’s instructions. Brieﬂy, 24–48 h after
Figure 2. Schematic representation of vectors used in the present study. (A)
pE3SP-bc, basic construct vector, containing the enhancer for Pol I-dependent
transcription, the sequence of mouse Pol I promoter (P) upstream of
transcription start, a transcription termination signal (Tx) and the KpnI and
BbsI sites for cloning purposes. (B) pE3SP-MCS vector contains a multiple
cloning site for additional cloning versatility. (C) pE3SP-shLuc and pE3SP-
Erk2 express short hairpin RNAs targeting firefly luciferase and Erk2,
respectively.
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pensed per well on a 24-well plate. Culture plates were incu-
bated for 15 min at room temperature, and 50 ml of the cell
lysate were used to assess luciferase activities. The reconsti-
tuted 50· Stop&Glo substrate was diluted 1:100 with Stop
&Glo buffer. To the cell lysate in the microtiter plate,
50 ml of LARII reagent were added (Microlite). Finally,
50 ml Stop&Glo reagent were applied to the lysates.
Western blot analysis
Western blot analysis was performed with protein extracts
from lipid-mediated transfected HN9 and electroporated
IDG3.2 ES cells. HN9 cells were collected 36–48 h after
transfection. Cells were washed once with cold PBS,
collected in 500 ml PBS using a cell scraper and transferred
into an Eppendorf tube. Following centrifugation, cells were
resuspended in Ampuwa water with protease inhibitors
(Roche Mini). Cells from 3 wells of a 6-well plate were pooled
in a total volume of 60 ml and sonicated. The lysates were
cleared by centrifugation (5 min/16.000 · g/4 C) and the pro-
tein content was quantiﬁed by Bradford reagent (Bio-Rad).
IDG3.2 ES cells from each 10 cm plate were lysed at 48 h
after transfection in 500 ml lysis buffer [2% SDS, 50 mM Tris
(pH 6.8), 50 mM DTT, 10% glycerol, protease inhibitors
(Roche Mini), 0.01% bromophenol blue]. Protein concentra-
tion was determined in lysis buffer without dye using the
BCA assay kit (Pierce).
From both cell types, 20 mg of each protein lysate were
separated by gel electrophoresis (SDS–PAGE) and trans-
ferred onto an immobilon polyvinylidene diﬂuoride (PVDF)
membrane (Millipore, Bedford, MA). Membranes were
blocked with 5% non-fat dried milk powder (Nestle ´, Vevey,
Switzerland) in TBS/T (0.05% Tween-20; Bio-Rad) for 2 h at
room temperature. The primary antibody recognizing ERK
1/2 as epitope (p44/42 MAP kinase, Thr202/Tyr204, Cell
Signaling Technology, Beverly, MA) was diluted 1:1000 in
TBS/T with 5% non-fat dried milk and incubated for 2 h at
room temperature. Afterwards, the blots were washed two
times for 10 min each with washing buffer (TBS/T) and
then incubated with horseradish peroxidase
(HRP)-conjugated anti-rabbit antibody (GE Healthcare,
Buckinghamshire, UK). The secondary antibody was diluted
1:4000 in TBS/T 5% non-fat dried milk), incubated for 2 h
at room temperature and unbound antibody was removed
by washing as above. The immune complex formed was
detected by ECL Plus (GE Healthcare, Buckinghamshire,
UK) according to the manufacturer’s protocol and the chemi-
luminescent signal was exposed to X-ray ﬁlm (Fuji Photo
Film, Tokyo, Japan). We performed a standard curve using
deﬁned steps of increased luminescence activity to assess
the linear range of the used ﬁlms. For further analysis, only
ﬁlms with optical densities in the estimated linear range of
the ﬁlm were used and scanned with a CanoScan 9900F.
The band intensities were ﬁnally quantiﬁed using TINA
Software (Raytest).
RESULTS
We present here a new vector suitable for expression of
shRNAs. Dicer processes shRNAs to siRNAs, which serve
as effector molecules in gene silencing (22). In order to be
successfully recognized and processed by Dicer, shRNAs
need to satisfy strict sequence and structure requirements.
In particular, it is very important to ﬁx precisely the transcrip-
tion initiation and termination points, so that no nucleotide
overhangs are present at either end of the resulting hairpin.
The rules governing Pol I-dependent transcription have
been extensively studied, making the design of such an exact
transcript possible (18). Mouse Pol I promoter encompasses
sequences downstream of the transcription start, which are,
however, not required for efﬁcient transcription. Only the
presence of a purine nucleotide at position +1 appears to be
indispensable (23). The transcription termination point is
also precisely determined, being 15 bp upstream from the
so called Sal box terminator (23). The Pol I minigene on
pW contains a complete mouse Pol I promoter and several
additional sequences between promoter and transcription
termination point. The cloning strategy aimed at removing
these additional sequences (Figure 1). After a two-step PCR
procedure, we subcloned the Pol I promoter with termination
sequences (Tx) into either pW or pE3SP backbone. The latter
contains an enhancer sequence, which increases the efﬁciency
of Pol I-dependent transcription (21). We called these vectors
pW-bc and pE3SP-bc, respectively (Figure 2A). Between the
promoter and the termination sequence Tx, these vectors
contain KpnI and BbsI sites, which were used to insert
a MCS, resulting in plasmids pW-MCS and pE3SP-MCS,
respectively (Figure 2B). The two BbsI sites of the pE3SP-
MCS were used for cloning of the short hairpin sequence
targeting ﬁreﬂy luciferase. The sequence is the same as
published by Paddison et al. (24). The construct was termed
pE3SP-shLuc. Plasmid pE3SP-MCS was used as control in
experiments with silencing ﬁreﬂy luciferase and Erk2
(Figures 2, 4 and 5; see below). The BbsI restriction enzyme
offers the advantage that the cleavage site is positioned
outside the recognition sequence of the nuclease; conse-
quently, no strict sequence requirements are needed for the
exact cleavage at the desired position. Moreover, BbsI
Figure 3. In vitro transcription assay using plasmids pE3SP-shLuc and pU6-shLuc in nuclear extracts. Assays were done in absence or presence of a-amanitin, a
specific inhibitor of Pol II- and Pol III-dependent transcription. (A) The expected band of 60 nt, corresponding to the expressed shRNA. (B) Additional fragment
of 150 nt in length, resulting from pU6-shLuc (Pol III-dependent) transcription. (C) 5S rRNA transcript (Pol III-dependent), used as a positive control for assay,
and inhibition by a-amanitin. Asterisk indicates an unspecific signal, inherent to the transcription from nuclear extract of FM3A cells.
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allowing directional cloning.
Next, we checked for the expression of the shLuc hairpin
in an in vitro transcription assay using whole nuclear extracts.
pE3SP-shLuc was used as a template, and
32P-labeled UTP
was incorporated into the primary transcript. As expected,
a fragment of 60 nt was detected, corresponding to the unpro-
cessed hairpin precursor shLuc (Figure 3A), but not the
mature siRNAs. Same results were obtained in an in vitro
transcription assay using nuclear extracts, partially puriﬁed
by DEAE ion exchange chromatography (data not shown).
The lack of the mature siRNA in the nucleus is consistent
with the notion that ﬁnal processing to siRNA by Dicer
takes place in the cytoplasm. As previously suggested
(25,26), the Pol I promoter might contain cryptic recognition
sites for other types of polymerases, in particular Pol II. How-
ever, in our case, transcription was not sensitive to treatment
with a-amanitin, an inhibitor of both Pol II- and Pol III-
dependent, but not of Pol I-dependent transcription. This
observation strongly suggests that transcription from
pE3SP-shLuc was indeed mediated by Pol I activity. In
contrast, when the Pol III promoter-containing pU6-shLuc
(Figure 3A and B) and 5S rRNA (Figure 3C) were used
as templates, the transcription was completely inhibited by
a-amanitin. Notably, two a-amanitin-sensitive signals were
observed, when using pU6-shLuc as a template. The 60 nt
transcript corresponded to the expected shLuc transcript,
while the transcript of 150 nt indicates that initiation or/and
termination of transcription have occurred at yet unidentiﬁed
sites.
Then, functional efﬁciency of pE3SP-shLuc in mediating
silencing was investigated. We co-transfected pE3SP-shLuc
into the mouse hippocampal cell line HT22 with the vectors
pGL3-Con expressing ﬁreﬂy luciferase (the target of shLuc)
and pRL-SV40 expressing Renilla luciferase, which serves
as an internal reference to normalize transfection efﬁciency.
The pE3SP-shLuc construct was able to speciﬁcally suppress
the activity of ﬁreﬂy luciferase by 86% (Figure 4A).
This efﬁciency of suppression was comparable to the Pol III-
driven vector pU6-shLuc (24). The effect was dose-dependent
for both silencing constructs and reached its optimal efﬁciency
at a silencer to reporter ratio of 10:1 (data not shown).
Unlike Pol II and Pol III, Pol I transcription exhibits
a remarkable species speciﬁcity, e.g. between mouse and
human (19). To test whether this species speciﬁcity is main-
tained in the Pol I-dependent silencing constructs, silencing
efﬁciencies of pE3SP-shLuc and pU6-shLuc were compared
Figure 4. Pol I-dependent shRNA induces species-specific gene silencing.
(A) Twenty four-well plates of HT22 mouse hippocampal cells were
transfected with 80 ng/well of plasmid that directs the expression of firefly
(pGL3-Con, Promega), 8 ng/well of plasmid expressing Renilla (pRL-SV40,
Promega) luciferase and 800 ng/well of the indicated DNA. Luciferase
activities were assayed 48 h after transfection using the dual luciferase assay.
Ratios of firefly to Renilla luciferase activities were normalized to a control
transfected with vector pcDNA3, and the control ratio was set to 1. The
average of two independent experiments is shown, and each experiment was
performed in duplicate; error bars indicate SD. pE3SP-MCS and pU6 are
empty vectors for corresponding shLuc-expressing plasmids pE3SP-shLuc
and pU6-shLuc, respectively. ***P < 0.001 Statistical significance was
evaluated using the Student’s t-test. (B) Species specificity of Pol I-dependent
gene silencing. Twenty four-well plates of HT22 mouse hippocampal cells or
HEK293 human embryonic kidney cells were transfected and the luciferase
expression was measured as in (A). Ratios of firefly to Renilla luciferase
activities were normalized to a control transfected with pBluescript vector.
The average of two independent experiments is shown, and each experiment
was performed in duplicate; error bars indicate SD. ***P < 0.001,
**P < 0.005. (C) Species specificity of Pol I-dependent gene silencing.
Twenty four-well plates of HeLa human epithelial cells, Neuro-2a mouse
neuroblastoma cells or HN9 mouse embryonic hippocampal cells were
transfected, and luciferase expression was measured as in (A). Ratios of
firefly to Renilla luciferase activities are expressed as a percentage of the
control sample that was transfected with the accordant empty expression
vector (pU6 for pU6-shLuc and pE3SP-MCS for pE3SP-shLuc). The average
of two independent experiments is shown, and each experiment was
performed in triplicate; error bars indicate SDs. Statistical analysis was done
using the Student’s t-test and asterisks indicate significant difference from the
empty vector control. ***P < 0.001.
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Pol III promoter-driven silencer pU6-shLuc was efﬁcient
in cell lines of both species, pE3SP-shLuc was only active in
mouse, but completely silent in human cells (Figure 4B). In
order to distinguish the cell line-speciﬁc effect from the
species-speciﬁc one, we repeated this experiment in two addi-
tional mouse (HN9 and Neuro-2a), and one human (HeLa)
cell lines. Again, the silencing was only efﬁcient in mouse
cells, and absent in the human cell line (Figure 4C). This
observation is a strong indication that transcription relies
indeed on Pol I-mediated mechanisms.
Finally, we tested our new expression cassette for the
capacity to silence an endogenous gene. As a target, we
took Erk2, a p42 MAP kinase. The hairpin sequence was
already tested for the silencing activity in the Pol III
promoter-driven vector (R. Ku ¨hn, unpublished data). We
subcloned the shRNA, targeting Erk2, into the pE3SP-MCS
vector backbone, and tested it for silencing activity in the
IDG3.2 mouse ES cells and the HN9 mouse cell line
(Figure 5). pE3SP-shLuc could signiﬁcantly down-regulate
the expression of Erk2, although the efﬁciency of silencing
was lower as compared to Pol III-based U6-shErk2. Silencing
was also highly speciﬁc, as two hairpins targeting unrelated
sequences were unable to produce any effect on Erk2 expres-
sion (pE3SP-shCon in Figure 5). We could reproduce these
ﬁndings in independent experiments with transfection of
silencers in HN9 mouse cell line, where both Pol III and
Pol I shRNAs showed similar effects in Erk2 down-regulation
(data not shown).
DISCUSSION
In this work, we generated a ribosomal minigene-based
vector for expression of shRNA under the control of
a mouse Pol I promoter. We showed the presence of the prim-
ary transcript of correct length expressed from this new
vector, termed pE3SP-shLuc. We also demonstrated the
functionality of our system in efﬁcient silencing of ﬁreﬂy
luciferase gene in mouse but not in human cells by using
the pE3SP-shLuc. Finally, we proved the efﬁcacy and
speciﬁcity of the expression vector in silencing the endoge-
nous Erk2 expression. The formation of the primary transcript
is not sensitive to inhibition by the Pol II- and Pol III-speciﬁc
toxin a-amanitin. This proves that the expression is initiated
by a Pol I-speciﬁc promoter, and not by cryptic promoters for
class II and class III RNA polymerases, whose activity might
interfere with Pol I activity, as suggested previously (25,26).
Interestingly, we found both the expected and longer prim-
ary transcripts, when a Pol III-dependent vector was used as
a template in in vitro transcription assay. This fact might sug-
gest a read-through from the plasmid, probably due to leaky
transcription termination in this vector. It was noted that the
termination of transcription of Pol III relies strongly on the
exact sequence of the termination signal and the proximity
of the promoter (27,28). As the shRNA insert is very short,
it might lead to interference between the enzymatic
machineries responsible for transcription initiation and
termination. It would be interesting to investigate whether
this longer transcript is exported to the cytoplasm and can
serve as a template for further processing by Dicer, resulting
in the generation of functional siRNAs.
The species speciﬁcity of Pol I-dependent transcription
provides an important advantage in terms of experimental
biosafety, as compared to other types of vectors. RNAi-
mediated down-regulation is frequently used to systemati-
cally reveal the function of unknown genes, often using
viral vectors, such as lentivirus (29–32). Currently used
lentiviral vectors are designed to inactivate themselves once
integrated into the genome. However, they still preserve the
capacity to infect cells, including those of the human experi-
menter. The use of the mouse-speciﬁc Pol I promoter, which
is silent in human cells, represents a considerable advantage.
The next logical step in the development of Pol I-based
expression vectors will be the generation of the Tet-inducible
cassette to allow a regulated knock-down.
Pol III-based vectors are now extensively used to express
shRNAs in numerous systems (33). However, an alternative
method to express short RNA molecules may be required
Figure 5. Pol I-dependent shRNA induces silencing of endogenous gene
expression. (A) Western blot using 20 mg of protein extracts from
electroporated IDG3.2 ES cells. A total of 50 mg of each of the plasmids
pU6-shErk2, pE3SP-shErk2, pE3SP-shCon and pE3SP-MCS were trans-
fected. The western blot shows the expected double-band for Erk1 (upper
band) and Erk2 (lower band). Erk2 is specifically down-regulated in the
samples from the transfected Pol III-driven (first lane) and Pol I-driven
(second lane) RNAi expression vectors. Erk1 expression remains unaffected
by the introduced RNAi and control vectors (lanes 3 and 4). (B)
Quantification of band intensities in western blot shown in (A). The
numerical values from the band intensities of the Erk2 signals were
normalized to those of Erk1 (mean ± SD; Student’s t-test: ***P < 0.001,
**P < 0.01). There is a significant and strong down-regulation of Erk2 by
shRNAs either derived from Pol III (first column) or Pol I promoters (second
column). Unrelated shRNAs (third column) and empty expression vectors
(fourth column) show no statistical effect on the expression of Erk2.
e10 Nucleic Acids Research, 2007, Vol. 35, No. 2 PAGE 6 OF 8for particular experiments. A need to screen or modify Pol III
promoters in order to obtain a strong and reliable inhibition in
a particular cell type or organ has been reported (34,35).
Occasionally, irreversible silencing of Pol III-dependent tran-
scription was observed in stable expression systems. Thus, it
would be desirable to systematically compare different Pol
III- with Pol I-dependent vectors regarding efﬁciency, stabil-
ity and toxicity issues.
To further broaden the scope of Pol I-driven expression
vectors, we constructed other minimal ribosomal minigene
vectors containing a MCS. Potentially, they can be used to
express other types of functional RNA molecules, such
as snoRNAs or viral RNAs (23). Finally, it would be desir-
able to generate a reporter vector, expressing for example
luciferase downstream of an IRES signal for cap-independent
translation. Up to now, the attempts to create such a reporter
largely failed because of above-mentioned reservations
concerning the presence of cryptic Pol II recognition sites
in ribosomal minigenes. Only one publication reported a con-
struction of such a vector, based on human Pol I promoter
(36). However, our results strongly point to the speciﬁcity
of Pol I-dependent transcription from our vectors.
In conclusion, we believe that our Pol I-driven expression
vectors will be a useful addition to the palette of RNAi-based
tools for silencing gene function.
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